- Preclinical development
- Clinical trials
- Disease Pathogenesis and Biomarkers
- Antiviral Resistance
- Regulatory Issues
- Diagnostics
- Antivirals and Monoclonal antibodies
Abstract submission closed on 14 September 2018 - Late-breaking abstracts will be accepted up to 31 October 2018
Notification of acceptance to be sent by 26 September 2018
Publication: Upon submission of an abstract, the author provides consent to allow ISIRV to publish the abstract in the Programme/Abstract Book, and posted on the ISIRV-AVG website 1 month prior to the conference.
Co-Author Approval: Ensure that all co-authors approve of the abstract submission, publication, and potential presentation. Abstracts cannot be changed or withdrawn after 14 September 2018.
Author Disclosure: All abstract authors are required to disclose any conflict of interest.
Changes to Abstract: You are able to edit your abstract until the submission deadline. After the submission deadline, only minor abstract changes (author or institution changes, disclosure, keyword or questionnaire updates) are allowed. The deadline for minor updates and all withdrawals is the 14 September 2018. Any corrections, withdrawals and/or changes will not be accepted after this date.
ENQUIRIES: Please email: lidadesouza@isirv.org